Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Comparison 2020 to 2021
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Comment by Golddetectoron Mar 01, 2022 4:52pm
143 Views
Post# 34472724

RE:RE:RE:RE:RE:Comparison 2020 to 2021

RE:RE:RE:RE:RE:Comparison 2020 to 2021As I mentioned earlier, we are more advanced than last year this time so the valuation should be more than 20c which was the sp last year at this time. Just last we spent 30M to reach here which is current MC. Forget about the previous 10 years of development. Investors are a bit worked out with The delay in Reborn enrolment which I should agree is disappointing but keep in mind the results are good so far and we are continuing with it. We needed 20 patients total and it started in may so it should have finished by now so the concern is legitimate but to sell at these levels with positive results do not make a lot of sense to me. As for Reduvo wait for final official approval from health Canada nothing is holding that. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities